Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Solar UV-Induced Skin Cancer Inhibitor

Technology #20170106

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
SKH-1 hairless mice treated with doses of vehicle with or without ADA-07 were applied topically to the dorsal area 1 h before SUV exposureDorsal trunk skin samples harvested and stained with H&E (left panels) or with an antibody to detect PCNA (right panels)Potent TOPK inhibitor
Categories
Researchers
Zigang Dong, MD, PhD
Professor, The Hormel Institute
External Link (cbs.umn.edu)
Ann M. Bode, PhD
Professor, The Hormel Institute
External Link (www.hi.umn.edu)
Kanamata Reddy, PhD
Research Associate, The Hormel Institute
Managed By
Kevin Anderson
Technology Licensing Officer 612-624-8293
Patent Protection

US Patent Pending
Publications
ADA-07 Suppresses Solar Ultraviolet–Induced Skin Carcinogenesis by Directly Inhibiting TOPK
Molecular Cancer Therapeutics , 16(9); 1–12, September 2017

Highly effective inhibitor of solar UV-induced skin cancer

ADA-07 is a novel potent T-LAK cell-originated protein kinase (TOPK) inhibitor that effectively suppresses solar ultraviolet (SUV) induced skin carcinogenesis. The novel compound, 5-((1s, 3s)-adamantan-1-yl)-3-(hydroxyimino) indolin-2-one, directly inhibits TOPK, an upstream activator of mitogen-activated protein kinase (MAPK) cascades involved in inflammation, DNA damage and tumor development. Testing shows ADA-07 is a promising chemopreventive or potential therapeutic agent against SUV-induced skin carcinogenesis.

TOPK inhibitor may prevent and treat SUV-induced skin cancer

T-LAK cell-originated protein kinase (TOPK), an oncogenic protein involved in various cellular functions, is highly expressed in many cancers. While evidence suggests that inhibiting TOPK might be useful in cancer chemoprevention and treatment, very few effective TOPK inhibitors have been discovered. Targeting SUV-induced signaling could be an effective chemoprevention and chemotherapy strategy against skin cancer. ADA-07 is a T-LAK cell-originated protein kinase (TOPK) inhibitor that may prevent and treat SUV-induced skin carcinogenesis by directly targeting (inhibiting) TOPK.

Phase of Development

  • In Vivo / animal studies

Benefits

  • Suppresses solar ultraviolet (SUV) induced skin carcinogenesis
  • Promising chemopreventive or potential therapeutic agent

Features

  • T-LAK cell-originated protein kinase (TOPK) inhibitor
  • Directly inhibits TOPK, an upstream activator of mitogen-activated protein kinase (MAPK)
  • cascades involved in inflammation, DNA damage and tumor development

Applications

  • Sunscreens
  • Solar ultraviolet (SUV) induced skin cancer prevention and treatment
  • Treatment of high risk cancer patients (i.e., immunosuppressed)
  • Post-surgery applications to prevent recurrence


Interested in Licensing?
The University relies on industry partners to scale up technologies to large enough production capacity for commercial purposes. The license is available for this technology and would be for the sale, manufacture or use of products claimed by the issued patents. Please contact Kevin Anderson to share your business needs and technical interest in this technology and if you are interested in licensing the technology for further research and development.